Q-omics provides the consensus-scored GPR45 profile across patient tissues and cancer cell-line models. GPR45 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GPR45 is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, GPR45 RNA expression shows 17,008 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KIRP, and UVM as cancer lineages where GPR45 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR45 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR45 survival associations across molecular data types. GPR45 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR45 RNA expression–survival associations across cancer types. High GPR45 expression shows unfavorable associations in KIRC, KICH and MESO, but favorable associations in UCS, LGG and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GPR45 RNA expression.
This table summarizes GPR45 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for GPR45. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR45 shows lower tumor expression in THCA, BRCA and KICH and higher tumor expression in KIRP, KIRC and BLCA. The KIRP box plot shows higher GPR45 RNA expression in tumor versus normal tissue (log2 FC = +1.317, t-test p < 0.001).
This table shows molecular features associated with GPR45 in patient tissues and cancer cell lines. In patient samples, GPR45 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR45 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and OESOPHAGUS.
